Owlstown Text-Only

Daniel A. Wilkenfeld

Associate Professor
Go to full site
Home
Publications

Ethical Considerations in Communicating Alzheimer’s Disease Neuroimaging Biomarker Test Results to Symptomatic Individuals

Journal article

Daniel A. Wilkenfeld, Staci L. Orbell, Jennifer H. Lingler
Neurotherapeutics, vol. 18, 2021, pp. 673--685
View PDF
Cite

Cite

APA   Click to copy
Wilkenfeld, D. A., Orbell, S. L., & Lingler, J. H. (2021). Ethical {Considerations} in {Communicating} {Alzheimer}’s {Disease} {Neuroimaging} {Biomarker} {Test} {Results} to {Symptomatic} {Individuals}. Neurotherapeutics, 18, 673–685.

Chicago/Turabian   Click to copy
Wilkenfeld, Daniel A., Staci L. Orbell, and Jennifer H. Lingler. “Ethical {Considerations} in {Communicating} {Alzheimer}’s {Disease} {Neuroimaging} {Biomarker} {Test} {Results} to {Symptomatic} {Individuals}.” Neurotherapeutics 18 (2021): 673–685.

MLA   Click to copy
Wilkenfeld, Daniel A., et al. “Ethical {Considerations} in {Communicating} {Alzheimer}’s {Disease} {Neuroimaging} {Biomarker} {Test} {Results} to {Symptomatic} {Individuals}.” Neurotherapeutics, vol. 18, 2021, pp. 673–85.

BibTeX   Click to copy 

@article{wilkenfeld2021a,
  title = {Ethical {Considerations} in {Communicating} {Alzheimer}’s {Disease} {Neuroimaging} {Biomarker} {Test} {Results} to {Symptomatic} {Individuals}},
  year = {2021},
  journal = {Neurotherapeutics},
  pages = {673--685},
  volume = {18},
  author = {Wilkenfeld, Daniel A. and Orbell, Staci L. and Lingler, Jennifer H.}
}